Compare Gilead Sciences, Inc. (GILD) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Direxion Daily Semiconductor Bull 3X Shares trades at $142.07. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Direxion Daily Semiconductor Bull 3X Shares pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| GILD | SOXL | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $155.80 | $300.77 |
52-Week Low | $110.56 | $24.91 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
SOXL, the Direxion Daily Semiconductor Bull 3X Shares ETF, surged 9.35% to $142.16 amid renewed semiconductor sector optimism. The ETF remains in a technical bearish trend despite the daily rally, with moving averages signaling caution. Recent news highlights significant government semiconductor funding and AI-driven demand catalysts, though the leveraged structure amplifies volatility risks. Financial ratios are unavailable as this is a leveraged ETF tracking semiconductor stocks rather than a traditional company.
SOXL offers aggressive exposure to semiconductor sector rebounds but carries elevated risk due to 3x daily leverage. The current technical setup suggests caution despite positive sentiment around AI chip demand. Key risks include sector volatility, leverage decay, and geopolitical tensions affecting semiconductor supply chains. Investors should understand the specialized nature of leveraged ETFs before considering positions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
